Deferred Income Tax Expense (Benefit) of CRESCENT BIOPHARMA, INC. from 31 Dec 2024 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
CRESCENT BIOPHARMA, INC. annual and quarterly Deferred Income Tax Expense (Benefit) in USD history and change rate from 31 Dec 2024 to 31 Dec 2025.
  • CRESCENT BIOPHARMA, INC. Deferred Income Tax Expense (Benefit) for the quarter ending 31 Dec 2024 was $0.
Source SEC data
View on sec.gov
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), Quarterly (USD)

CRESCENT BIOPHARMA, INC. Annual Deferred Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $0 01 Jan 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY

CRESCENT BIOPHARMA, INC. Quarterly Deferred Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $0 20 Sep 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.